Liraglutide (Saxenda / Victoza) vs Semaglutide
Liraglutide (Saxenda / Victoza) vs Semaglutide (Ozempic / Wegovy): daily first-generation GLP-1 vs its weekly successor. Weight loss, dosing burden, and FDA status.
The verdict
Semaglutide is the newer, stronger take on the same idea. Both are single-receptor GLP-1 agonists and both are FDA-approved, but in a head-to-head trial weekly Semaglutide produced more than double the weight loss of daily Liraglutide, and one weekly shot beats a daily injection for most people. Liraglutide still earns a place as the older, well-tracked option, and it often wins on insurance coverage or for someone who tolerates a daily titration better. Choosing fresh with both covered, Semaglutide is the stronger pick; Liraglutide is the fallback when cost or coverage decides it.
Liraglutide is the daily-injection GLP-1 that came before Semaglutide. Sold as Saxenda for weight loss and Victoza for diabetes. Same family as Wegovy/Ozempic but you inject it every day instead of weekly. Less convenient, but covered by some insurance plans that don't cover the weekly versions.
Semaglutide is the first wave of modern weight-loss drugs, sold as Ozempic and Wegovy. Single-receptor version of Tirzepatide. Slightly less effective and slightly rougher side effects, but well-studied and widely available.
Which one should you pick?
Pick Liraglutide (Saxenda / Victoza) if patients on insurance plans that cover saxenda but not wegovy or users who don't tolerate weekly semaglutide titration.
Pick Semaglutide if beginners to glp-class peptides or users with insurance coverage on wegovy / ozempic.
Still torn between Liraglutide (Saxenda / Victoza) and Semaglutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.